ライフサイエンスコーパス: kidney transplant

1 ry at all US centers including our own (open kidney transplant).

2 (highest in liver transplants and lowest in kidney transplants).

3 ith quadrimembral amputations and a previous kidney transplant.

4 donor-derived KS in the recipient of a liver-kidney transplant.

5 ration decreasing the cost of pancreas after kidney transplant.

6 rate and odds of receiving a deceased donor kidney transplant.

7 t has a high propensity for recurrence after kidney transplant.

8 t, there are racial disparities in access to kidney transplant.

9 used by persistent hyperparathyroidism after kidney transplant.

10 y to CKD, which was followed by a preemptive kidney transplant.

11 ents who received their first deceased donor kidney transplants.

12 wn to trigger chronic allograft rejection in kidney transplants.

13 ual proportions of living donor, DBD and DCD kidney transplants.

14 differentiate rejection from other injury in kidney transplants.

15 8; P < 0.001) were associated with increased kidney transplants.

16 idates, and 1198 candidates (31.7%) received kidney transplants.

17 ld potentially improve graft survival in DCD kidney transplants.

18 ormed a total of 1553 adult first and second kidney transplants-1021 with a living donor, 532 with a

19 database who received a first deceased-donor kidney transplant (1995-2013).

20 hundred sixty-five adults with PCKD received kidney transplants (303 tx alone, 161 simultaneous, 27 p

21 th children receiving a well HLA-matched DBD kidney transplant (83%, 95% CI, 80-86%, log rank test P

22 r children receiving a poorly HLA-matched LD kidney transplant (88%, 95% confidence interval [95% CI]

23 We conclude that, at 1 year after kidney transplant, a risk model of graft survival that i

24 Although spontaneous kidney transplant acceptance/tolerance occurs in mice an

25 gdom, donation after circulatory death (DCD) kidney transplant activity has increased rapidly, but ma

26 Local expansion in DCD kidney transplant activity improves survival outcomes fo

27 We report how increased DCD kidney transplant activity influenced waitlisted outcome

28 recipient and the contralateral kidney to a kidney transplant alone (KTA) recipient (cohort from Feb

29 osis caused 1.3% of the graft losses in open kidney transplant and 0% in the RKT group.

30 for AUC and Cmax in both individuals with a kidney transplant and those with a liver transplant.

31 rolling hypercalcemia in these patients with kidney transplants and persistent hyperparathyroidism.

32 7.0 years, 10,004 children had at least one kidney transplant, and 1675 deaths occurred.

33 recipient is matched, or even in need of, a kidney transplant, and deceased donor initiated chains i

34 nfection, decompensated cirrhosis, liver and kidney transplants, and end-stage liver disease.

35 plement-dependent endothelial cell injury in kidney transplants, as assessed by expression of endothe

36 to treat study of 2587 candidates listed for kidney transplant at a single transplant center over 7 y

37 ve cohort included 163 636 adults listed for kidney transplant before December 31, 2011.

38 a cohort of 189,944 patients who received a kidney transplant between 2001 and 2013.

39 registry, patients who have received second kidney transplants between 1997 and 2009 were included.

40 an [SD] age, 49.6 [15.3] years) who received kidney transplants between 2004 and 2012, 488 (0.4%) had

41 neous pancreas and kidney and pancreas after kidney transplants between January 1994 and July 2013.

42 ing data, we identified first deceased donor kidney transplants between October 1, 1987, and December

43 pancreas transplant alone and pancreas after kidney) transplants between 2000 and 2013.

44 ripts, and studied their expression in human kidney transplant biopsies with AMR and in an extended h

45 ion after donation after cardiac death (DCD) kidney transplants, but the impact of DGF on graft outco

46 Kidney transplant candidates (KTCs) must provide informe

47 haring data, we examined retrospectively all kidney transplant candidates (n = 369 103) and recipient

48 trospective cohort study in first-time adult kidney transplant candidates (N=161,308) using data from

49 odel to calculate likelihood of outcomes for kidney transplant candidates and demonstrate how this in

50 We evaluated 202,195 kidney transplant candidates and recipients from a linka

51 ncy, causes, and optimal management of PH in kidney transplant candidates and recipients.

52 izing the assessment and management of PH in kidney transplant candidates and recipients.

53 We found that women and men kidney transplant candidates engaged an equivalent type

54 cross large areas of the United States, many kidney transplant candidates spend over 5 years waiting

55 Kidney transplant candidates undergoing transplant evalu

56 a from 2003 to 2012 for adult deceased donor kidney transplant candidates was analyzed to evaluate pa

57 has limited efficacy for desensitization in kidney transplant candidates when up to 16 doses is give

58 f body surface area) in 10 highly sensitized kidney transplant candidates with alloantibodies against

59 es transplant eligibility by reducing BMI in kidney transplant candidates, but the effect of surgical

60 endent predictor of mortality in wait-listed kidney transplant candidates.

61 eater market competition was associated with kidney transplant center spatial clustering (P < 0.001).

62 In multivariable analysis, more kidney transplant centers (incidence rate ratio [IRR], 1

63 A significant proportion of kidney transplant centers are identified as low performi

64 dney transplants were performed at 229 adult kidney transplant centers in 58 DSAs.

65 (PSR), January 2013 to July 2015 among adult kidney transplant centers.

66 If the kidney transplant community's goal of "one transplant fo

67 1993 and 2012 were extracted from the French kidney transplant database.

68 oss was substantially higher (deceased donor kidney transplant [DDKT] without delayed graft function

69 an influence diagram that models generalized kidney transplant decisions and show how the influence d

70 The creation of "vouchers" for future kidney transplants enables living donation to occur when

71 e recently established that HIV-1 can infect kidney transplant epithelial cells in the absence of det

72 Beyond the first posttransplant year, 3% of kidney transplants fail annually.

73 of 138 patients who initiated dialysis after kidney transplant failure between 1995 and 2014.

74 The majority of early kidney transplant failure in adults is due to allograft

75 ies have facilitated compatible living-donor kidney transplants for end-stage renal disease patients

76 a from 13,789 patients who received a second kidney transplant from 1995 to 2011, of which 3868 had o

77 e years after HSCT, he received a preemptive kidney transplant from his father.

78 e-center evidence that patients who received kidney transplants from HLA-incompatible live donors had

79 the survival benefit for 1025 recipients of kidney transplants from HLA-incompatible live donors who

80 r-specific antibody: 89.2% for recipients of kidney transplants from incompatible live donors who had

81 ved longevity of HIV-positive individuals, a kidney transplant has become a viable option for many wh

82 health while waitlisted, and disparities in kidney transplant has not been investigated.

83 Children receiving a DCD kidney transplant have good renal allograft survival at

84 lysis and Transplant Registry who received a kidney transplant in Australia between January 1, 2000,

85 pplied minimally invasive surgery to perform kidney transplant in individuals with body mass index (B

86 More than 40% of patients awaiting a kidney transplant in the UK are sensitised with human le

87 time trends in average eGFR at 1 year after kidney transplant in the United States in a cohort of 18

88 It used 5% of deceased donor kidney transplanted in 2015.

89 s of HLA-matched and mismatched living donor kidney transplants in 3 medical centers using hematopoie

90 f a mutant strain in high-risk recipients of kidney transplants, including 168 seronegative recipient

91 hibitors (CNI) nephrotoxicity to progressive kidney transplant injury remains debated, with little lo

92 Lower eGFR 1 year after kidney transplant is associated with shorter allograft a

93 ched DBD kidney when a poorer HLA-matched LD kidney transplant is available.

94 decline in eGFR between years 1 and 3 after kidney transplant is common and strongly associated with

95 ge renal disease being relisted for a second kidney transplant is increasing worldwide.

96 Median historical time to kidney transplant is misleading because it does not conv

97 The success of kidney transplants is limited by the lack of robust impr

98 Among the 12,831 DCD kidneys transplanted, kidneys with WIT</=48 minutes had

99 al vascular disease (PVD) and survival among kidney transplant (KT) candidates is uncertain.

100 ysiologic reserve, is associated with longer kidney transplant (KT) length of stay (LOS), and modifie

101 Older patients with ESRD who receive a kidney transplant (KT) may develop post-KT dementia and

102 national case-control study that included 51 kidney transplant (KT) recipients diagnosed with early (

103 Prevalence and clinical outcomes of MGUS in kidney transplant (KT) recipients have been previously r

104 ior outcomes among black compared with white kidney transplant (KT) recipients.

105 Liver transplant (LT), kidney transplant (KT), and dual liver kidney (DLK) tran

106 al studies have described ED use rates among kidney transplant (KTx) recipients, and the factors asso

107 raft loss and death in African-American (AA) kidney transplant (KTX) recipients.

108 ith DGF: 10.815.221.4, P < 0.001; live donor kidney transplant [LDKT]: 18.136.774.2, P < 0.001) and m

109 ta2(neg) gammadelta T cells in recipients of kidney transplants may predict CMV infection resolution

110 Finally, in the preclinical pig kidney transplant model, intravenous injection of GC7 be

111 ade in a syngeneic and an allogeneic DCD rat kidney transplant model.

112 gnum 12+12 Cohort of patients who received a kidney transplant (n=1339).

113 ormation was obtained from Organ Procurement Kidney Transplant Network/United Network for Organ Shari

114 ording to quartiles of risk of mortality and kidney transplant on the basis of multivariable Cox mode

115 tibodies (DSAs) are associated with impaired kidney transplant outcome; however, whether these antibo

116 his therapy has the potential to improve DCD kidney transplant outcomes in the human setting.

117 Long-term kidney transplant outcomes remain suboptimal, delineatin

118 first week (UNOS-DGF), associates with poor kidney transplant outcomes.

119 ficant impact on graft survival of pediatric kidney transplants (P < 0.001).

120 olyomavirus was discovered in the urine of a kidney transplant patient and named BK virus.

121 Here we present an unusual case of a kidney transplant patient presenting with progressive ne

122 Kidney transplant patients aged <14 years were analyzed

123 e and approved by the health authorities for kidney transplant patients is belatacept (Nulojix), a fu

124 , and screening for urologic malignancies in kidney transplant patients is warranted, and as such, th

125 Currently, potential kidney transplant patients more often suffer from comorb

126 hormone levels were comparable in adolescent kidney transplant patients receiving low-exposure mTOR i

127 Kidney transplant patients showed lower IT infiltrates a

128 Kidney transplant patients treated with belatacept witho

129 In the open-label ELEVATE trial, kidney transplant patients were randomized at 10 to 14 w

130 De novo kidney transplant patients were randomized to generic ta

131 the US Renal Data System, we identified 3245 kidney transplant patients who underwent PCI between Apr

132 crovesicle concentration in the plasma of 95 kidney transplant patients with allograft dysfunction an

133 ults demonstrate a complex urinary virome in kidney transplant patients with multiple viruses with se

134 explored in a cross-sectional analysis in 59 kidney transplant patients with SCC on CNI (KT-CNI-SCC)

135 Following immunosuppression in kidney transplant patients, BK polyomavirus (BKV) has be

136 this study, we evaluate whether in tolerant kidney transplant patients, the increased IL-10 producti

137 human immunodeficiency virus/HCV coinfected kidney transplant patients.

138 nformation indicating clinical conditions of kidney transplant patients.

139 AMR-associated genes in plasma exosomes from kidney transplant patients.

140 tion in highly HLA sensitized (HS) pediatric kidney transplant patients.

141 All kidney transplanted patients from 2000 to 2011 (n = 1375

142 scular rejection (TCMVR) (Banff 4-II/III) in kidney transplanted patients.

143 birth outcomes in children fathered by male kidney transplanted patients.

144 Deceased-donor kidney transplants performed at the weekend do not have

145 Data on 240 024 kidney transplants performed between 1987 and 2009 were

146 Kidney transplants performed for pediatric recipients (a

147 utcomes, for which the proportion of DCD:DBD kidney transplants performed is lower (25%; p < 0.0001),

148 The pediatric kidney transplant population is at a particularly increa

149 tal stents (BMS) has not been studied in the kidney transplant population.

150 reappearance of anti-PLA2R antibodies after kidney transplant predicts development of recurrent dise

151 government-sponsored paid living donor (LD) kidney transplant program.

152 Georgia has the lowest kidney transplant rates in the United States and substan

153 rt (CYP3A5, ABCB1, and PXR) were analyzed in kidney transplant recipients (1995-2005, Leiden cohort,

154 we identified all adult (>/=18 years) first kidney transplant recipients (1996-2011) with ESRD attri

155 here were 13 trials (n = 9850) that included kidney transplant recipients (6 trials), patients who ha

156 sured by flow cytometry in 76 deceased donor kidney transplant recipients (DGF, n = 18; SGF, n = 34;

157 l acute kidney injury (AKI) occurred in four kidney transplant recipients (KDIGO grade 1: n = 3, grad

158 ittent hemodialysis treatment (CKD 5D) and 8 kidney transplant recipients (KT) with severe aortic val

159 opathy (PVAN) after BK virus reactivation in kidney transplant recipients (KTR) can compromise graft

160 associated with baseline viral serostatus in kidney transplant recipients (KTR) on sirolimus have not

161 orptiometry is used to assess bone health in kidney transplant recipients (KTR).

162 CMV infection in kidney transplant recipients (KTRs) has been associated

163 s (CMV)-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have been attributed

164 ute rejection and improves graft outcomes in kidney transplant recipients (KTRs).

165 escribe the results in a cohort of 10 stable kidney transplant recipients (median of 4.3 years posttr

166 TV load in the peripheral blood and AMR, 715 kidney transplant recipients (median, 6.3 years posttran

167 Pre- and postvaccination sera from kidney transplant recipients (n = 60) immunized with the

168 s in pediatric and adolescent deceased donor kidney transplant recipients aged 21 years or younger us

169 evalence proportions of 10%, 11%, and 18% in kidney transplant recipients and 10%, 9%, and 13% in liv

170 spective longitudinal study, we enrolled 168 kidney transplant recipients and 69 matched donors.

171 It remains uncertain whether kidney transplant recipients are a high-risk group for f

172 Approximately 200 000 kidney transplant recipients are living in the United St

173 interventions on death and graft failure in kidney transplant recipients are not feasible, because t

174 Thirty percent of kidney transplant recipients are readmitted in the first

175 ologies performed between 1998 and 2014 from kidney transplant recipients at the University of Maryla

176 tive observational study of 1996 adult first kidney transplant recipients between 1991 and 2010 in th

177 re (proximal humerus, forearm, hip) in adult kidney transplant recipients between 1994 and 2009, stra

178 r prospective cohort study of 83 nondiabetic kidney transplant recipients between 2008 and 2011.

179 ith an increased risk of graft loss in adult kidney transplant recipients but the association remains

180 y must be added to the current monitoring of kidney transplant recipients due to its relationship wit

181 sion analyses were performed on adult, first kidney transplant recipients during 1991 to 2010 (n = 14

182 lyomavirus (BKPyV) frequently reactivates in kidney transplant recipients during immunosuppressive th

183 al and transplant history from 977 prevalent kidney transplant recipients enrolled in the Malnutritio

184 Non-Hispanic black kidney transplant recipients experience a substantial di

185 Black kidney transplant recipients experience disproportionate

186 e relevance of these cells in 100 unselected kidney transplant recipients followed prospectively for

187 udy 56 076 adult Medicare-primary first-time kidney transplant recipients from December 1999 to Octob

188 etrospective cohort study of 948 nondiabetic kidney transplant recipients from January 1, 2000, to De

189 The risk of graft failure in young kidney transplant recipients has been found to increase

190 Although the management of kidney transplant recipients has greatly improved over r

191 enal Data System records of Medicare-insured kidney transplant recipients in 2000 to 2011 to determin

192 The care of kidney transplant recipients involves a balance between

193 tment of IL-2RAb in pediatric and adolescent kidney transplant recipients is associated with at least

194 lthough current immunosuppressive therapy in kidney transplant recipients is effective, dosing is con

195 chronic hepatitis C virus (HCV) infection in kidney transplant recipients is limited because of the r

196 chronic hepatitis C virus (HCV) infection in kidney transplant recipients is limited because of the r

197 e optimal maintenance dose of tacrolimus for kidney transplant recipients is unknown.

198 educing the risk of acute rejection in adult kidney transplant recipients is well established, a simi

199 Kidney transplant recipients may have a lower fracture r

200 Kidney transplant recipients often receive antibody indu

201 In the Spare-the-Nephron (STN) Study, kidney transplant recipients randomized about 115 days p

202 er prospective randomized study in which 288 kidney transplant recipients receiving tacrolimus and pr

203 In this cohort of de novo kidney transplant recipients receiving tacrolimus and pr

204 undertaken using single-antigen beads in 131 kidney transplant recipients returning to the transplant

205 his clinical trial, we randomized 90 de novo kidney transplant recipients shortly after transplantati

206 Our study included 86 DSA+ kidney transplant recipients subjected to protocol biops

207 y were to describe the evolution of HRQOL in kidney transplant recipients to search for subgroups wit

208 records, and Medicare claims data for 16 308 kidney transplant recipients transplanted 2006 to 2008,

209 opensity score matched cohort study of adult kidney transplant recipients transplanted between May 1,

210 timal use, we describe the largest series of kidney transplant recipients treated with prophylactic e

211 In this retrospective study of US kidney transplant recipients undergoing PCI, DES was ass

212 Longitudinal cohort study of kidney transplant recipients using a data set created by

213 denosumab to prevent bone loss in first-year kidney transplant recipients was associated with more fr

214 Forty kidney transplant recipients were 1:1 randomized to bela

215 In the phase II IM103-100 study, kidney transplant recipients were first randomized to be

216 -two heart, 34 liver, 79 kidney, and 5 liver-kidney transplant recipients who completed treatment for

217 tched cohort study of 52 of 1476 consecutive kidney transplant recipients who developed postoperative

218 lected crossmatch positive living donor HLAi kidney transplant recipients who received their transpla

219 Kidney transplant recipients with a pretransplant cancer

220 In a cohort of 242 kidney transplant recipients with acute allograft dysfun

221 registry was reviewed for adult living donor kidney transplant recipients with BMI of 40 kg/m or grea

222 Forty-four DSA-positive kidney transplant recipients with characteristic ABMR mo

223 avirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients with chronic genotype 1 or

224 Patients: Treatment-naive or -experienced kidney transplant recipients with chronic genotype 1 or

225 avirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients with chronic genotype 1 or

226 Treatment-naive or -experienced kidney transplant recipients with chronic genotype 1 or

227 Additionally, among 109 heart or kidney transplant recipients with CKD, those with higher

228 Thirteen kidney transplant recipients with complicated UTIs under

229 We identified 45 kidney transplant recipients with dnDSA detected between

230 In 42 kidney transplant recipients with functioning grafts who

231 d to have an acceptable safety profile among kidney transplant recipients with HCV genotype 1 or 4 in

232 d to have an acceptable safety profile among kidney transplant recipients with HCV genotype 1 or 4 in

233 human immunodeficiency virus/HCV coinfected kidney transplant recipients with ledipasvir-sofosbuvir

234 A group) with (i) 104 matched HLA-sensitized kidney transplant recipients with No DSA at D0 (No DSA g

235 We examined 254 consecutive kidney transplant recipients with positive virtual cross

236 with No DSA at D0 (No DSA group) and (ii) 47 kidney transplant recipients with preformed A, -B, -DR,

237 findings in the current study indicate that kidney transplant recipients with PV replication and smo

238 Kidney transplant recipients with urinary angiogenin amo

239 Among first kidney transplant recipients younger than 30 years in Fr

240 Of 7826 kidney transplant recipients, 271 (3%) were indigenous.

241 Among 2441 kidney transplant recipients, 31% experienced delayed gr

242 eded to identify the optimal DAA regimen for kidney transplant recipients, accounting for efficacy, t

243 R-146a in both allografts and urine of human kidney transplant recipients, and unilateral IRI in mice

244 e general population and in HCV-monoinfected kidney transplant recipients, but there are no data to g

245 In young kidney transplant recipients, elevated ABP is frequently

246 de novo donor-specific antibodies (dnDSA) in kidney transplant recipients, especially in those with s

247 Kidney transplant recipients, for example, have a 7-fold

248 al to become clinically useful surrogates in kidney transplant recipients, including functional T cel

249 er 1.73 m(2) among deceased and living donor kidney transplant recipients, respectively.

250 In prevalent kidney transplant recipients, serum TNF-alpha and IL6 we

251 lyomavirus (BKV) in urinary tract cancers in kidney transplant recipients, suggesting that BKV could

252 rvational study involving 319 deceased-donor kidney transplant recipients, we assessed variations in

253 risk of acute rejection and graft loss in AA kidney transplant recipients, whereas neither baseline n

254 rapid discontinuation of prednisone (RDP) in kidney transplant recipients.

255 e, and treatment of urologic malignancies in kidney transplant recipients.

256 as patients with end-stage renal disease and kidney transplant recipients.

257 dence and risk determinants of PTLD in Irish kidney transplant recipients.

258 nd the development of malignant neoplasms in kidney transplant recipients.

259 is the second leading cause of graft loss in kidney transplant recipients.

260 th remains the leading cause of mortality in kidney transplant recipients.

261 as further extended to peripheral B-cells in kidney transplant recipients.

262 ween BKV and urothelial carcinogenesis among kidney transplant recipients.

263 ust predictor of long-term graft function in kidney transplant recipients.

264 e associated with adverse outcomes in stable kidney transplant recipients.

265 l is an independent risk factor for NODAT in kidney transplant recipients.

266 ed the urine virome profile of BKV+ and BKV- kidney transplant recipients.

267 own about their association with outcomes in kidney transplant recipients.

268 r follow-up SAI predicted outcomes in non-AA kidney transplant recipients.

269 nts with advanced chronic kidney disease and kidney transplant recipients.

270 cardiovascular and kidney outcomes in stable kidney transplant recipients.

271 ul in assessing the risk of BKV infection in kidney transplant recipients.

272 ly noninvasive detection of AMR in pediatric kidney transplant recipients.

273 is important in the outpatient follow-up of kidney transplant recipients.

274 n, particularly within African American (AA) kidney transplant recipients; little is known about intr

275 and significantly improved renal function in kidney-transplant recipients.

276 Based on an analysis of 542 pediatric kidney transplants recorded by the UK Transplant Registr

277 on increased referral and improved equity in kidney transplant referral for patients on dialysis in G

278 al (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we inves

279 Chronic injury in kidney transplants remains a major cause of allograft lo

280 d to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADP

281 If possible, living donor pediatric kidney transplants should be performed from donors with

282 a South Africa study involving 27 HIV-to-HIV kidney transplants showed promise, with 3- and 5-year pa

283 abase records for 9916 simultaneous pancreas-kidney transplants (SPKT) performed between 2000 and 201

284 d IRDs later received non-IRD deceased donor kidney transplants; the median KDPI of these non-IRD kid

285 A retrospective analysis of kidneys transplanted through the KFTS was undertaken.

286 rge cohort of children and young adults with kidney transplant to estimate the prevalence of abnormal

287 considered for use as a surrogate outcome in kidney transplant trials.

288 ent of donors was undertaken in a specialist kidney transplant unit in Pakistan to identify risk and

289 Unfortunately, the kidney transplant waiting list has ballooned to over 100

290 From the UK adult kidney transplant waiting list, we selected crossmatch p

291 At the time of kidney transplant, we obtained and analyzed the sections

292 f death and higher likelihood of receiving a kidney transplant, we performed a cohort study of 469,57

293 About 152,071 kidney transplants were performed at 229 adult kidney tr

294 al failure, especially at the early phase of kidney transplant when ischemia-reperfusion injury and c

295 e cohort analysis of pairs of deceased donor kidney transplants where 1 kidney was allocated to a sim

296 ctive treatment for most is a combined liver-kidney transplant, which requires life-long immune suppr

297 PrEdiction (ESCAPE) Study in 75 consecutive kidney transplants who received 6-month protocol biopsie

298 e patient who presented for a deceased donor kidney transplant with incidental finding of complete in

299 ared survival of patients opting for an HLAi kidney transplant with that of similarly sensitised pati

300 Over 100 000 patients are waiting for a kidney transplant, yet 3159 kidneys were discarded in 20